Olema Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Olema Pharmaceuticals, Inc. (OLMA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are OLMA insiders buying or selling?
In the last 12 months, Olema Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 6 sales ($7.7M) — net selling of $7.7M. Since November 2020, Trabud has recorded 74 Form 4 filings for OLMA: 12 buys ($84.0M) and 62 sells ($100.6M).
Source: SEC EDGAR Form 4
Key Statistics (November 2020 – Jul 27, 2026)
Total Form 4 filings
74
SEC EDGAR
Insider filers
12
Insider buys (12)
$84.0M
Insider sells (62)
$100.6M
Insider sentiment
Net sellingNet insider flow of $16.6M in net selling since November 2020, and $7.7M in net selling over the last 12 months.
Recent OLMA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Cyrus Harmon | Director | Sale | 25.0K | $11.65 | $291.2K | SEC ↗ |
| Mar 6, 2026 | Shawnte Mitchell | CHIEF LEGAL OFFICER | Sale | 40.0K | $23.79 | $951.5K | SEC ↗ |
| Jan 22, 2026 | Cyrus Harmon | Director | Sale | 10.0K | $26.88 | $268.8K | SEC ↗ |
| Jan 17, 2026 | Cyrus Harmon | Director | Sale | 3.5K | $29.12 | $101.6K | SEC ↗ |
| Jan 16, 2026 | Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale | 103.8K | $28.70 | $3.0M | SEC ↗ |
| Jan 15, 2026 | David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | Sale | 110.0K | $28.25 | $3.1M | SEC ↗ |
| Sep 19, 2025 | Cyrus Harmon | Director | Sale | 25.0K | $8.19 | $204.8K | SEC ↗ |
| Jan 13, 2025 | Bain Capital Life Sciences Investors, LLC | 10% Owner | Purchase | 300.0K | $5.76 | $1.7M | SEC ↗ |
| Dec 18, 2024 | Graham G. Walmsley | Director | Sale | 1.4M | $6.75 | $9.5M | SEC ↗ |
| Dec 12, 2024 | Cyrus Harmon | Director | Sale | 16.4K | $9.03 | $148.0K | SEC ↗ |
| Dec 12, 2024 | David C. Myles | CH. DISCOV. & NON-CLIN DEV OFF | Sale | 26.1K | $9.01 | $234.9K | SEC ↗ |
| Dec 12, 2024 | Naseem Zojwalla | CHIEF MEDICAL OFFICER | Sale | 27.8K | $9.01 | $250.5K | SEC ↗ |
| Dec 12, 2024 | Shane William Charles Kovacs | CH. OPERATING & FINANCIAL OFF. | Sale | 35.2K | $9.01 | $316.7K | SEC ↗ |
| Dec 12, 2024 | Sean Bohen | PRESIDENT AND CEO | Sale | 109.5K | $9.01 | $986.4K | SEC ↗ |
| Nov 26, 2024 | Graham G. Walmsley | Director | Sale | 1.2M | $14.85 | $17.4M | SEC ↗ |
| Aug 5, 2024 | Senai Asefaw | 10% Owner | Sale | 2.4M | $14.92 | $35.8M | SEC ↗ |
| Jul 31, 2024 | Cyrus Harmon | Director | Sale | 5.0K | $15.57 | $77.9K | SEC ↗ |
| Jul 12, 2024 | Cyrus Harmon | Director | Sale | 5.0K | $12.26 | $61.3K | SEC ↗ |
| Jul 2, 2024 | Cyrus Harmon | Director | Sale | 20.0K | $10.77 | $215.4K | SEC ↗ |
| Jun 6, 2024 | Graham G. Walmsley | Director | Sale | 1.2M | $14.85 | $17.4M | SEC ↗ |
| Jun 5, 2024 | Cyrus Harmon | Director | Sale | 25.0K | $10.30 | $257.4K | SEC ↗ |
| May 7, 2024 | Cyrus Harmon | Director | Sale | 5.0K | $10.92 | $54.6K | SEC ↗ |
| May 2, 2024 | Cyrus Harmon | Director | Sale | 15.0K | $9.51 | $142.7K | SEC ↗ |
| Mar 29, 2024 | Cyrus Harmon | Director | Sale | 20.0K | $10.97 | $219.4K | SEC ↗ |
| Mar 4, 2024 | Cyrus Harmon | Director | Sale | 25.0K | $12.41 | $310.3K | SEC ↗ |
Showing the 25 most recent of 74 Form 4 filings for Olema Pharmaceuticals, Inc..
Most active OLMA insiders
- Cyrus Harmon29 filings
- Kinney Horn10 filings
- David C. Myles7 filings
- Sean Bohen7 filings
- Graham G. Walmsley5 filings
Ask anything about OLMA insider activity
Use Trabud's AI agent to query Olema Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me OLMA CEO purchases this year" or compare it against any other ticker.
Open the AI agentOLMA insider trading FAQ
Are Olema Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Olema Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 6 sales ($7.7M) — net selling of $7.7M. Since November 2020, Trabud has recorded 74 Form 4 filings for OLMA: 12 buys ($84.0M) and 62 sells ($100.6M). Over the full record that is net selling of $16.6M.
How many insiders trade OLMA stock?
12 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Olema Pharmaceuticals, Inc.. The most recent filing was accepted on Jul 27, 2026.
Where does Trabud get OLMA insider trading data?
All OLMA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.